{"id":295570,"date":"2026-08-04T00:00:00","date_gmt":"2026-08-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0031-2023-biopharma-migraine-current-treatment-treatment-algorithms-claims-data-analysis\/"},"modified":"2026-08-25T23:26:30","modified_gmt":"2026-08-25T23:26:30","slug":"algocg0031-2026-biopharma-migraine-current-treatment-treatment-algorithms-claims-data-analysis-migraine-prophylaxis-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0031-2026-biopharma-migraine-current-treatment-treatment-algorithms-claims-data-analysis-migraine-prophylaxis-us\/","title":{"rendered":"Migraine &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Migraine Prophylaxis (US)"},"content":{"rendered":"<p>Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients\u2019 quality of life. Our quantitative analysis of treatment patterns focuses on the prophylactic treatment of migraine, aimed at reducing the frequency, severity, and duration of migraine attacks and, in turn, reducing patients\u2019 level of disability and potentially increasing the responsiveness of breakthrough migraine attacks to acute treatment. Although generic <abbr title=\"antiepileptic drug\">AED<\/abbr>s, antidepressants, and beta blockers dominate the first three lines of therapy, our report provides insight into both the market-leading classes and the uptake of brands, such as <abbr title=\"calcitonin gene-related peptide\">CGRP<\/abbr> monoclonal antibodies and the <abbr title=\"calcitonin gene-related peptide\">CGRP<\/abbr>-targeted oral therapy Qulipta (AbbVie). Pfizer\u2019s Nurtec <abbr title=\"orally disintegrating tablet\">ODT<\/abbr> is not included in our primary analysis, as its acute and prophylactic use cannot be readily differentiated.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in prophylaxisna\u00efve migraine patients? What are the quarterly trends in prescribing among na\u00efve and recently treated patients?<\/li>\n<li>How have <abbr title=\"calcitonin gene-related peptide\">CGRP<\/abbr>-targeted therapies been integrated into the prophylactic treatment algorithm, and what is their source of business? What switching patterns exist between different <abbr title=\"monoclonal antibody\">MAb<\/abbr>s and between <abbr title=\"monoclonal antibody\">MAb<\/abbr>s and Qulipta?<\/li>\n<li>What percentage of prophylactically naive migraine patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of prophylactic therapy within two years of diagnosis?<\/li>\n<li>What is the split between prophylactic monotherapy and combination therapy in drugtreated migraine patients\u2014including the most common combinations\u2014and the productlevel compliance and persistency rates for each therapy?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy<\/li>\n<li>Evaluate your brand share against competitors<\/li>\n<li>Accurately assess your source of business<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Key drugs covered: <\/strong><\/p>\n<p>Aimovig, Emgality, Ajovy, Vyepti, Qulipta, Botox, topiramate <abbr title=\"extended release\">XR<\/abbr>, Trokendi <abbr title=\"extended release\">XR<\/abbr>, amitriptyline, propranolol<\/p>\n<p><strong>Key analyses:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Brand \/ therapy usage across longitudinal patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<li>Product-level patient flow charts<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-295570","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-migraine","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}